awz1066s
Small moleculeexperimental
Clinical trial activity
1 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2021 (NCT05084560)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- WolbachiaINHIBITOR
inhibitor - Wolbachia
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05084560 | Phase 1 | Nov 1, 2021 | Covance, Eisai, Royal Liverpool & Broadgreen University Hospitals NHS Truts, Subiaco Associates Limited, Sylexis, University of Liverpool |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Covance | For profit | 1 | 0 | 1 | 2021 |
| Eisai | For profit | 1 | 0 | 1 | 2021 |
| Royal Liverpool & Broadgreen University Hospitals NHS Truts | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Subiaco Associates Limited | For profit | 1 | 0 | 1 | 2021 |
| Sylexis | For profit | 1 | 0 | 1 | 2021 |
| University of Liverpool | Academic/Hospital | 1 | 1 | 1 | 2021 |
6 organizations
Page 1 / 1